Συγγραφείς:
Liapis, K.
Papadopoulos, V.
Vrachiolias, G.
Galanopoulos, A.G.
Papoutselis, M.
Papageorgiou, S.G.
Diamantopoulos, P.T.
Pappa, V.
Viniou, N.-A.
Kourakli, A.
Τsokanas, D.
Vassilakopoulos, T.P.
Hatzimichael, E.
Bouronikou, E.
Ximeri, M.
Pontikoglou, C.
Megalakaki, A.
Zikos, P.
Panayiotidis, P.
Dimou, M.
Karakatsanis, S.
Papaioannou, M.
Vardi, A.
Kontopidou, F.
Harchalakis, N.
Adamopoulos, I.
Symeonidis, A.
Kotsianidis, I.
Λέξεις-κλειδιά:
azacitidine; beta 2 microglobulin; antineoplastic antimetabolite; azacitidine, aged; assessment of humans; blast cell; blood transfusion; bone marrow cell; cancer prognosis; cancer specific survival; cytogenetics; drug efficacy; Endothelial Activation and Stress Index; estimated glomerular filtration rate; female; high risk patient; human; intermediate risk patient; International Prognostic Scoring System; Letter; low risk patient; major clinical study; male; myelodysplastic syndrome; overall survival; risk factor; adult; follow up; middle aged; myelodysplastic syndrome; prognosis; survival analysis; very elderly, Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis
